Researchers have identified an antibody that neutralizes Sudan virus, one of the most deadly human pathogens caused by ebolavirus. The new findings suggest a key spot for neutralizing ebolaviruses, which could lead to the development of effective vaccines and antibody-based therapies.
Researchers at Virginia Tech have identified four US strains of the hepatitis E virus in farmed rabbits, closely related to genotype 3, which can spread from animals to humans. The discovery raises concerns about the potential for zoonotic transmission and food safety risks.
A new three-dimensional model of measles virus helps explain unaccounted observations in its life cycle. The study found matrix protein forms helical tubes around the viral genome and nucleocapsid, regulating replication and genome movement.
Research finds West Nile virus transmission is highest in urbanized and agricultural habitats, with robins and specific mosquito species playing a crucial role. The virus has had an impact on human health, particularly due to its ability to target abundant bird species.
Researchers have discovered a new Ebola-like virus, Lloviu, in bats from northern Spain, which is the first filovirus native to Europe. The study reveals that Lloviu may be a cause for concern as it was detected in deceased bats with signs of an immune response, but not in healthy bats.
Research reveals that West Nile virus transmission is highest in urbanized and agricultural areas, with the American robin playing a key role as a 'super-spreader'. Mosquito species that feed on robins are more important in transmission than other birds.
A collaborative research team has developed an effective therapy against Hendra virus, giving an anti-virus human monoclonal antibody therapy after exposure protected animals from lethal disease. The study demonstrates promising results and offers a real potential treatment for Hendra virus infection in people.
A neutralizing human monoclonal antibody, m102.4, has been developed to protect against Hendra virus infection, showing promise as a potential treatment for severe illness and death in humans. The antibody attacks a critical component of the virus, preventing its infection of cells.
A team of researchers from Boston University's School of Medicine and College of Engineering have been awarded a $4.8 million NIH grant to develop a low-cost, multiplexed virus detection platform capable of rapidly detecting viral pathogens such as Ebola, Lassa Fever, and Marburg. The resulting diagnostic platform should be able to det...
Scientists have successfully tested a bivalent vaccine that protects against both rabies and Ebola in mice, offering a promising solution for Africa's healthcare challenges. The vaccine is built on the same platform as the approved rabies vaccine and has several advantages over existing Ebola candidates.
Researchers have identified a protein used by Ebola virus to gain entry into cells and begin replicating, providing a new target for antiviral drugs. This discovery may lead to the development of more stable and effective treatments for Ebola hemorrhagic fever (EHF), currently caused by one of the deadliest known viruses affecting humans.
Researchers identify Niemann-Pick C1 as critical protein for Ebola virus entry, paving the way for potential antiviral treatments. The discovery improves chances of developing drugs that directly combat Ebola infections.
Researchers at Brigham and Women's Hospital identified a novel small molecule that inhibits Ebola virus entry into cells by more than 99 percent. The target of the inhibitor is the cell protein Niemann-Pick C1, which is critical for EboV infection.
Scientists at Albert Einstein College of Medicine have discovered a key cellular protein, Niemann-Pick C1, that is essential for the Ebola virus to infect cells. The finding suggests a possible strategy for blocking infection due to Ebola virus, which has killed up to 90% of those infected in some outbreaks.
Researchers identified Niemann-Pick C1 as a critical cellular protein for Ebola virus entry, allowing scientists to develop antiviral drugs. The discovery offers a promising strategy to combat the deadly virus.
Research suggests Hepatitis G virus may cause liver damage and cancer, contrary to FDA's initial declaration in 1997. A review of scientific literature shows the virus is prevalent globally, linked to hepatitis, cirrhosis, and hepatocellular carcinoma.
Veterinary researcher Scott Kenney received a prestigious USDA grant to investigate the molecular mechanisms of pathogenesis behind porcine reproductive and respiratory syndrome virus. The two-year grant aims to better understand how the virus causes reproductive failure in sows and respiratory diseases in piglets.
A newly discovered human antibody recognized multiple strains of the flu virus, providing a promising lead for developing a longer-lasting vaccine. The antibody, dubbed CH65, binds tightly to the receptor pocket on the influenza virus, making it less affected by mutations.
Researchers track both clinical cases of West Nile Virus and infected mosquito populations to identify 'danger zones' and predict outbreaks. They also analyze the virus's genetic types, dynamics, and mobility to better understand its migration patterns.
Researchers at the University of Leeds have discovered a powerful way to suppress hepatitis C by targeting different parts of the virus. Two prototype small molecule drugs, p7 inhibitors, attack the virus in distinct ways, suggesting they could be used together with 'direct-acting' drugs for more effective treatment.
Researchers found that Zaire ebolavirus replicates in pigs, causing disease and transmitting the virus to unexposed animals. Pigs with respiratory symptoms shed high viral loads, posing a risk of transmission to humans.
A team of researchers identified TIM-1 as the cellular protein that acts as a receptor for Ebola and Marburg viruses. An antibody targeting TIM-1 blocks infection by both viruses, potentially providing a way to prevent initial infection and limit outbreak spread.
Researchers at the University of Illinois Chicago have discovered a family of small molecules that bind to the Ebola virus's outer protein coat and inhibit its entry into human cells. The findings demonstrate a potential breakthrough in preventing Ebola infection, with further studies planned to confirm efficacy.
A new type of vaccine is being developed that can trick the body into developing immunity against polio, with no risk of causing or spreading the disease. The replica virus particle will be designed to look and behave like the real virus but contain no genetic material.
Boston University researchers developed a simple diagnostic tool that can quickly identify Ebola and Marburg viruses in blood samples. The biosensor is ultra-portable, fast, and can detect viruses with little to no sample preparation.
Researchers found fragments of viruses, including hepatitis B and Ebola, integrated into the genomes of insects and animals. The discovery could provide insights into the evolutionary history of viruses and inform approaches for controlling disease.
A purified form of a modified sugar chain called COAM is shown to enhance early-stage immune defenses in mice against deadly virus infections. The compound speeds the response of white blood cells at the early stage of infection, almost completely blocking the killer virus.
Researchers at the University of Illinois have discovered a new virus in switchgrass that can cause mosaic and yellow streak symptoms, reducing photosynthesis and biomass yield. The virus, Marafivirus, is related to Maize rayado fino virus and has the potential to affect other crops.
Researchers have discovered the world's largest marine virus, Cafeteria roenbergensis virus, which has a genome larger than some cellular organisms. This complex 'mimi-like' virus infects an ecologically important planktonic predator and challenges the traditional boundary between living and non-living entities.
Researchers at Iowa State University and the Ames Laboratory discovered the flu virus uses a shuttle mechanism to relay protons through a channel, necessary for infection. This finding may lead to designing drugs that stop protons from moving through the channel.
Researchers are conducting a phase II clinical trial using reovirus, a common virus that causes mild symptoms, to target and kill specific tumor cells with KRAS or EGFR mutations. The goal is to exploit the virus's ability to replicate in cancer cells while minimizing harm to healthy cells.
The study found that H5N1 survives longer at cooler temperatures and low humidity, persisting up to two weeks. The virus also thrives on certain surfaces like glass and steel, potentially surviving for up to two months.
Researchers developed novel antisense therapies that protected monkeys infected with deadly Ebola or Marburg viruses, with survival rates over 90%. The treatments were administered up to one hour after exposure and showed promise for treating accidental infections in laboratory or hospital settings.
Researchers found HIV-1 virus alters in semen versus blood through two distinct mechanisms, affecting its replication and transmission.
A recent study found that human and other vertebrate genomes contain ancient sequences from deadly virus families, Ebola/Marburgviruses and Bornaviruses. These integrations were likely mediated by movable elements and may provide a selective advantage to the host species, potentially protecting against future infections.
In a study of rhesus macaques, the experimental Marburg vaccine showed 100% protection when administered 24 hours after lethal exposure, and 66.7% survival rate when treated 48 hours post-infection. The vaccine works by activating the immune system to fight off the target virus.
Scientists have successfully prevented monkeys exposed to the deadly Ebola virus from dying of hemorrhagic fever using a genetic material-based treatment. The study suggests that such protection could also be possible in humans, offering new hope for combating the highly contagious and lethal disease.
A groundbreaking study has shown that a novel treatment using small interfering RNAs can protect monkeys from lethal Ebola virus infection after exposure. The treatment was found to be well-tolerated and offered complete protection in some cases, paving the way for further research and potential human trials.
A newly developed experimental Ebola vaccine has shown protection in monkeys against a newer Ebola virus species identified in 2007. The vaccine induces a robust T-cell response that can cross-react with other Ebola virus species.
A new study reveals that the human immune system's defences against dengue fever can actually help the virus infect more cells. This finding could lead to the development of an effective vaccine by avoiding certain antibodies produced in response to the virus.
Researchers have proven that subneutralizing levels of dengue virus antibodies exacerbate the disease, contradicting the normal function of antibodies. This finding has major implications for developing a vaccine against dengue virus, which annually infects 50-100 million people worldwide.
A common plant virus attracts aphids by elevating the odor cue of infected plants without changing it. The insects transmit the disease efficiently despite leaving quickly, implying a persistent mode of transmission beyond agriculture.
Researchers have developed a broad-spectrum antiviral compound that can stop a wide range of highly dangerous viruses, including those causing HIV, Ebola, and hepatitis C. The compound works by altering the lipid envelope of enveloped viruses, making them unable to fuse with host cells.
Scientists have developed an experimental VLP vaccine that protects macaques and mice against chikungunya virus, a debilitating disease with no current treatment. The vaccine, using non-infectious virus-like particles, elicits immune responses and provides complete protection from infection.
A new study by Imperial College London discovered a virus called vaccinia spreading four times more quickly than previously believed. The virus uses a novel mechanism to spread rapidly between cells, making it harder to target with antiviral drugs.
The BC Centre for Disease Control has launched a genomic surveillance project to study the evolution of the pandemic H1N1 flu virus in British Columbia. Researchers will compare the genetic sequences of BC's influenza viruses with those from other regions to understand how mass gatherings like the Olympics impact the virus' evolution.
Researchers discovered that the Ebola virus uses a protein called VP35 to mask its RNA, evading the host cell's immune response. This unique mechanism makes Ebola highly deadly and difficult to treat.
Scripps Research scientists have determined the structure of the Ebola virus's critical protein VP35, which blocks the human immune system. The discovery may lead to new drug therapies and vaccines for Ebola infection.
Researchers aim to understand how the JC virus attaches to host cells, with potential treatments for progressive multifocal leukoencephalopathy (PML). The five-year grant will explore the virus's interaction with serotonin receptors in the brain.
A recent large-scale swine flu outbreak at the US Air Force Academy provided valuable insights into the natural behavior of the nH1N1 virus, including shedding patterns. The study found that viable virus shedding occurred in about one quarter of confirmed patients and persisted even after symptom-free periods.
Researchers found that levels of the 2009 H1N1 virus rose more quickly than seasonal flu strains, causing more severe disease. The novel virus was also transmitted more easily from infected to uninfected ferrets.
Research published in Cell Host and Microbe reveals a minor reduction in CD45 levels provides protection against both Ebola virus and Bacillus anthracis. Mice expressing reduced CD45 levels showed enhanced viral clearance and increased protection against infection.
Montana State University researchers study Sulfolobus turreted icosahedral virus (STIV) and its effects on host cells. The virus forms pyramid-like projections on the surface of infected cells, releasing progeny in a previously unknown manner.
The 1918 influenza pandemic created a viral dynasty that persists to this day, with all human-adapted influenza A viruses being descendents of the founding virus. The novel 2009 H1N1 virus is yet another manifestation of this enduring viral family.
Scientists discovered two critical biochemical pathways for Ebola virus entry into cells and developed inhibitors to block them. The UTMB team prevented Ebola infection in cell culture experiments, a crucial step towards developing the first therapy for the deadly disease.
Recent research on H5N1 avian influenza virus reveals its mechanisms, epidemiology, and transmission dynamics. Understanding the host-virus interaction is crucial for developing effective control measures.
Researchers at USC have identified a critical molecular mechanism that allows the influenza virus to evade the body's immune response system. The study reveals that the virus targets the ubiquitin ligase TRIM25, inhibiting its ability to activate RIG-I and trigger an alarm signal.
A Kansas State University researcher has found that the 1918 Spanish flu pandemic virus and the current swine influenza virus are closely related, with the former adapting to pigs and resulting in the latter. The study suggests that pigs may have played a role in maintaining and spreading the virus.
Researchers found that after reassortment with a human influenza virus, an avian flu virus requires relatively few mutations to spread rapidly between mammals by respiratory droplets. This process is similar to the formation of the current swine flu outbreak, suggesting a potential link between avian and human influenza viruses.
Researchers from Durham University have successfully mapped the high-resolution structure of the matrix protein, a critical component of enveloped viruses like RSV. This breakthrough could lead to the development of new biochemical tools to treat respiratory ailments and other viral infections.